Formation Bio logo

Formation Bio

Challenger

Formation Bio is an AI-native pharmaceutical company that acquires clinical-stage drug assets and accelerates their development to market using proprietary AI and operational technology; raised $372M in a 2024 Series D;

Best for: AI-Native Drug Development & Clinical Asset Acceleration
Life Sciences & BioTechAI-Native Drug Development & Clinical Asset AccelerationWebsiteUpdated May 2026

Company Overview

About Formation Bio

Formation Bio (formerly TrialSpark) is a New York-based AI-native pharmaceutical company founded in 2016 by Nicky Popp and Benjamine Liu. The company operates at the intersection of artificial intelligence and drug development, acquiring clinical-stage pharmaceutical assets — compounds that have demonstrated early safety and efficacy in human trials — and applying proprietary AI and operational technology to accelerate their development timelines and reduce costs. Rather than discovering new drug targets from scratch, Formation Bio's model focuses on execution excellence: identifying undervalued clinical assets and getting them to patients faster and more cheaply than traditional pharma development organizations can.

Business Model & Competitive Advantage

Formation Bio's technology platform encompasses AI-assisted clinical trial design and execution, patient recruitment optimization, site selection algorithms, and regulatory strategy tools. Its operational approach integrates these AI capabilities with a multidisciplinary in-house team of pharma veterans, data scientists, and engineers who manage clinical programs end-to-end. The company originally operated under the name TrialSpark, focused primarily on making clinical trials faster through decentralized and site optimization approaches, before pivoting to its current asset acquisition and AI-powered development model under the Formation Bio brand.

Competitive Landscape 2025–2026

The company raised a $372M Series D in 2024, bringing total funding to over $600M, from investors including a16z Bio, 8VC, and Sequoia Capital, among others. Formation Bio also entered a significant partnership with Pfizer — a $100M+ collaboration — to co-develop select clinical-stage assets using Formation Bio's AI and development capabilities alongside Pfizer's resources. This big-pharma validation partnership represents a key milestone, positioning Formation Bio not just as an independent drug developer but as a platform that major pharmaceutical companies can engage to accelerate their own pipelines.

Founded
2016
Curated content • Fact-checked and verified

Key Differentiators

Strong Challenger

Formation Bio is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.

Frequently Asked Questions

Similar Brands

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Regeneron logo

Regeneron

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingFortune500

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m

Compare Formation Bio with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Formation Bio

Claim This Profile

Are you from Formation Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Formation Bio Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Formation Bio vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →